{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:57:50Z","timestamp":1761101870894},"reference-count":42,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.vaccine.2008.12.033","type":"journal-article","created":{"date-parts":[[2009,1,14]],"date-time":"2009-01-14T04:23:41Z","timestamp":1231907021000},"page":"1601-1608","source":"Crossref","is-referenced-by-count":14,"title":["The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine"],"prefix":"10.1016","volume":"27","author":[{"given":"Sven Arne","family":"Silfverdal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claes","family":"Hemlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iiro","family":"Jokinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2008.12.033_bib1","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1017\/S0950268806007199","article-title":"Burden of paediatric invasive pneumococcal disease in Europe, 2005","volume":"135","author":"McIntosh","year":"2007","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2008.12.033_bib2","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1016\/j.vaccine.2007.01.021","article-title":"Prevenar vaccination: review of the global data, 2006","volume":"25","author":"Center","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.12.033_bib3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1183\/09031936.01.00084401","article-title":"Pneumococcal vaccination: current and future issues","volume":"18","author":"Ortqvist","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.vaccine.2008.12.033_bib4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1651-2227.2001.tb00784.x","article-title":"Prevention of pneumococcal disease in children. Pneumococcal conjugate vaccines: their use globally could have a major impact on public health","volume":"90","author":"Kyaw","year":"2001","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.vaccine.2008.12.033_bib5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00431-001-0907-3","article-title":"Pneumococcal disease in western Europe: burden of disease, antibiotic resistance and management","volume":"161","author":"Cartwright","year":"2002","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.vaccine.2008.12.033_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2807\/esm.11.09.00646-en","article-title":"Pneumococcal disease surveillance in Europe","volume":"11","author":"Pebody","year":"2006","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2008.12.033_bib7","unstructured":"Pneumococcal infection (invasive infection), Swedish Institute for Infectious Disease Control, 2007, Accessed 11 October 2007: http:\/\/www.smittskyddsinstitutet.se\/in-english\/statistics\/pneumococci-infection-invasive-infection\/."},{"key":"10.1016\/j.vaccine.2008.12.033_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1473-3099(06)70520-5","article-title":"Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old","volume":"6","author":"Jefferson","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2008.12.033_bib9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/00365540310013315","article-title":"Capsular types and antibiotic susceptibility of invasive Streptococcus pneumoniae among children in Sweden","volume":"35","author":"Hedlund","year":"2003","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2008.12.033_bib10","unstructured":"National Board of Health and Welfare. SOSFS 2008:7 (M). Socialstyrelsens f\u00f6reskrifter om \u00e4ndring i f\u00f6reskrifterna (SOSFS 2006:22) om vaccination av barn; http:\/\/www.sos.se\/sosfs\/2008_7\/2008_7.htm."},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2008.12.033_bib11","article-title":"Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults","volume":"24","author":"Black","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.12.033_bib12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1586\/14760584.3.4.433","article-title":"Cost-effectiveness studies of pneumococcal conjugate vaccines","volume":"3","author":"McIntosh","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2008.12.033_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00019053-200321080-00005","article-title":"Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany","volume":"21","author":"Claes","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2008.12.033_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10198-006-0013-6","article-title":"Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects","volume":"9","author":"Lloyd","year":"2008","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.vaccine.2008.12.033_bib15","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.vaccine.2004.08.051","article-title":"Pneumococcal pneumonia in the UK\u2014how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV)","volume":"23","author":"McIntosh","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.12.033_bib16","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1016\/j.vaccine.2006.04.042","article-title":"Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program","volume":"24","author":"Wisl\u00f8ff","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.12.033_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00365540802014872","article-title":"Cost-effectiveness analysis of a universal vaccination program with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden","volume":"40","author":"Bergman","year":"2008","journal-title":"Scand J Inf Dis"},{"key":"10.1016\/j.vaccine.2008.12.033_bib18","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1016\/S0264-410X(03)00031-8","article-title":"The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine","volume":"21","author":"McIntosh","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.12.033_bib19","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00006454-199909000-00004","article-title":"Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers","volume":"18","author":"Shinefield","year":"1999","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2008.12.033_bib20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2008.12.033_bib21","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/00006454-200209000-00005","article-title":"Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia","volume":"21","author":"Black","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2008.12.033_bib22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.inf.0000129685.04847.94","article-title":"Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente","volume":"23","author":"Black","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2008.12.033_bib23","unstructured":"Statistics Sweden (Statistiska centralbyr\u00e5n), accessed January, 2007: http:\/\/www.scb.se\/templates\/Product_25785.asp."},{"key":"10.1016\/j.vaccine.2008.12.033_bib24","unstructured":"The Norwegian Surveillance System for Communicable Diseases (MSIS), The Norwegian Institute of Public Health (NIPH), personal communication."},{"key":"10.1016\/j.vaccine.2008.12.033_bib25","unstructured":"Statistics Norway, Accessed May, 2007: http:\/\/statbank.ssb.no\/statistikkbanken\/Default_FR.asp?PXSid=0&nvl=true&PLanguage=1&tilside=selecttable\/MenuSelS.asp&SubjectCode=02."},{"key":"10.1016\/j.vaccine.2008.12.033_bib26","unstructured":"National Board of Health and Welfare and Epidemiology Cf, Accessed http:\/\/www.socialstyrelsen.se\/en\/."},{"key":"10.1016\/j.vaccine.2008.12.033_bib27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1017\/S0950268898001575","article-title":"Increase in paediatric acute otitis media diagnosed by primary care in two Finnish municipalities\u20141994-5 versus 1978-9","volume":"121","author":"Joki-Erkkila","year":"1998","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2008.12.033_bib28","unstructured":"Henriques B, Swedish Institute for Infectious Disease Control. 2007."},{"key":"10.1016\/j.vaccine.2008.12.033_bib29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/00365540110026818","article-title":"Invasive pneumococcal infections in Southwestern Sweden: a second follow-up period of 15 years","volume":"33","author":"Dahl","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2008.12.033_bib30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM200102083440602","article-title":"Efficacy of a pneumococcal conjugate vaccine against acute otitis media","volume":"344","author":"Eskola","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2008.12.033_bib31","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(07)60564-9","article-title":"Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis","volume":"369","author":"Grijalva","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2008.12.033_bib32","unstructured":"Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease\u2014United States, 1998\u20132003. MMWR Morb Mortal Wkly Rep, 2005;54:893\u20137."},{"key":"10.1016\/j.vaccine.2008.12.033_bib33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/00365540500532852","article-title":"Serotypes of Streptococcus pneumoniae isolated from blood and cerebrospinal fluid related to vaccine serotypes and to clinical characteristics","volume":"38","author":"Berg","year":"2006","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2008.12.033_bib34","unstructured":"The Swedish Institute for Health Economics, http:\/\/www.ihe.se\/english\/index.htm."},{"key":"10.1016\/j.vaccine.2008.12.033_bib35","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/00365540500321512","article-title":"Economic evaluation of pneumococcal conjugate vaccination in Finland","volume":"37","author":"Salo","year":"2005","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2008.12.033_bib36","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/01.inf.0000222403.42974.8b","article-title":"Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the united states incorporating herd effects","volume":"25","author":"Ray","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2008.12.033_bib37","series-title":"Health technology assessment (HTA)","article-title":"Effects and costs of pneumococcal conjugate vaccination of Belgian children","author":"Beutels","year":"2006"},{"key":"10.1016\/j.vaccine.2008.12.033_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3111\/200407085092","article-title":"The clinical and economic impact of pneumococcal conjugate vaccine associated herd immunity in Canada","volume":"7","author":"Ford","year":"2004","journal-title":"J Med Econ"},{"key":"10.1016\/j.vaccine.2008.12.033_bib39","series-title":"Economic consequences of acute otitis media in Sweden","author":"Hemlin","year":"2003"},{"key":"10.1016\/j.vaccine.2008.12.033_bib40","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0140-6736(06)69637-2","article-title":"Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case\u2013control study","volume":"368","author":"Whitney","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2008.12.033_bib41","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/j.vaccine.2008.03.087","article-title":"Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway","volume":"26","author":"Vestrheim","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.12.033_bib42","series-title":"Economic evaluation of heptavalent pneumococcal conjugate vaccine in Sweden","author":"Berg","year":"2003"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08017581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08017581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T02:27:55Z","timestamp":1558060075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X08017581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0264410X08017581"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2008.12.033","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}